HIV/AIDS
New HIV/AIDS research from J. Berenguer et al outlined
Published in AIDS Weekly, November 3rd, 2008
"The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. We conducted an open-label, randomized study to compare the noninferiority of ddI/3TC/EFV with the lamivudine- zidovudine tablet and EFV (COM/EFV), both administered with food to improve tolerability and convenience," scientists in Madrid, Spain report.
"Patients were stratified by HIV-1 RNA level of <5.0 log(10) or >= 5.0 log(10) copies/mL. The primary end point was the percentage of patients with an HIV-1 RNA level of <50 copies/mL at week 48, determined...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-11-03)
More Articles from AIDS Weekly
- NIH/National Institute of Allergy and Infectious Diseases
Markers of inflammation and blood-clotting tied to hazards of intermittent HIV treatment - Scripps Research Institute
Scripps research team sheds light on immune system suppression - Cervical Cancer
Research data from Okayama University update understanding of cervical cancer - CytoDyn, Inc.
CytoDyn Files New IND for Cytolin - HIV/AIDS
New HIV/AIDS findings from University of Rochester described - HIV/AIDS
New HIV/AIDS study findings reported from K.G. Saskova and co-authors - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
